Only few drugs are used in clinical obesity management, including Orlistat, a pancreatic lipase inhibitor, Phentermine/topiramate, a sympathomimetic, appetite suppressant, Lorcaserin, a 5-HT2C receptor activator, Naltrexone/bupropion, a transmitter reuptake inhibitor and Liraglutide, a glucagon-like peptide 1 (GLP-1) analogue. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.